Alexza begins Phase 2a study of AZ-002 for ARS-related epilepsy management Alexza Pharmaceuticals.

Alexza begins Phase 2a study of AZ-002 for ARS-related epilepsy management Alexza Pharmaceuticals, Inc. ARS takes place in a subset of sufferers with epilepsy who knowledge breakthrough seizures frequently, despite treatment with a regular regimen of anti-epileptic drugs http://cialisprix.net/ . Our team has been dealing with a few of the leading opinion leaders in neuro-scientific epilepsy to finalize our advancement technique for AZ-002, stated James V. Cassella, PhD, Executive Vice President, Development and Research, and Chief Scientific Officer of Alexza.

For example, a study might appear in a data source for all sufferers who got chemotherapy and then another round of chemotherapy more than six weeks following the first, imagining a second circular defines recurrent disease. Or a study might look in a database for all individuals with a recently discovered secondary tumor, imagining that all patients with a secondary tumor have recurrent disease. Our study implies that both methods are leave substantial area for improvement, says Debra Ritzwoller, PhD, wellness economist at the Kaiser Permanente Colorado Institute for Health Study and investigator at the University of Colorado Cancers Center.